Work

Total psoriasis regression in a patient with chronic myeloid leukemia treated using nilotinib

Year: 2025

Type: article

Abstract: Chronic myeloid leukemia (CML) treatment has been revolutionized over last 20 years because of tyrosine kinase inhibitors (TKIs) and patients with CML now have life expectancy of general population. Chronic TKI treatment may cause adverse effects (AEs) that vary in frequency and severity. Nilotinib shows common AEs with metabolic changes and skin AEs. Here, we present a case report of patient who experienced full psoriasis regression while treated with nilotinib. Dose reductions and an attempt to stop nilotinib treatment resulted in prompt psoriasis reappearance. This is the first documented case of positive effect of nilotinib on psoriasis.

Source: Annals of Hematology

DOI: 10.1007/s00277-025-06228-x

Authors: Tomáš Horňák, Daniela Žáčková, Jiří Mayer

Institutions: Masaryk University, University Hospital Brno

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $4,590